93 related articles for article (PubMed ID: 24974897)
1. Elevated serum free light chains do not predict outcome of elderly patients with aggressive CD20(+) B-cell lymphomas.
Achenbach M; Bittenbring JT; Ziepert M; Regitz E; Ott G; Rosenwald A; Pfreundschuh M; Altmann B; Held G
Br J Haematol; 2014 Nov; 167(3):430-4. PubMed ID: 24974897
[No Abstract] [Full Text] [Related]
2. Association of CD20 levels with clinicopathological parameters and its prognostic significance for patients with DLBCL.
Suzuki Y; Yoshida T; Wang G; Togano T; Miyamoto S; Miyazaki K; Iwabuchi K; Nakayama M; Horie R; Niitsu N; Sato Y; Nakamura N
Ann Hematol; 2012 Jul; 91(7):997-1005. PubMed ID: 22249209
[TBL] [Abstract][Full Text] [Related]
3. Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma.
Fabbri A; Gozzetti A; Rigacci L
Cancer; 2011 Aug; 117(15):3530; author reply 3531. PubMed ID: 21287541
[No Abstract] [Full Text] [Related]
4. Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma.
Musolino A; Boggiani D; Panebianco M; Vasini G; Salvagni S; Franciosi V; Ardizzoni A
Cancer; 2011 Mar; 117(5):964-73. PubMed ID: 20960528
[TBL] [Abstract][Full Text] [Related]
5. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial.
Peyrade F; Jardin F; Thieblemont C; Thyss A; Emile JF; Castaigne S; Coiffier B; Haioun C; Bologna S; Fitoussi O; Lepeu G; Fruchart C; Bordessoule D; Blanc M; Delarue R; Janvier M; Salles B; André M; Fournier M; Gaulard P; Tilly H;
Lancet Oncol; 2011 May; 12(5):460-8. PubMed ID: 21482186
[TBL] [Abstract][Full Text] [Related]
6. FcgammaRIIB expression in diffuse large B-cell lymphomas does not alter the response to CHOP+rituximab (R-CHOP).
Camilleri-Broët S; Mounier N; Delmer A; Brière J; Casasnovas O; Cassard L; Gaulard P; Christian B; Coiffier B; Sautès-Fridman C
Leukemia; 2004 Dec; 18(12):2038-40. PubMed ID: 15470484
[No Abstract] [Full Text] [Related]
7. An unresectable Klatskin's tumor?
Hartl J; Werner T; Schramm C
Gastroenterology; 2014 Jun; 146(7):e3-4. PubMed ID: 24780210
[No Abstract] [Full Text] [Related]
8. Composite diffuse large B-cell lymphoma and CD20-positive peripheral T-cell lymphoma.
Yamazaki S; Fujioka Y; Nakamura F; Ota S; Shinozaki A; Yamamoto G; Kamikubo Y; Nannya Y; Ichikawa M; Fukayama M; Kurokawa M
Pathol Int; 2011 Nov; 61(11):662-6. PubMed ID: 22029677
[TBL] [Abstract][Full Text] [Related]
9. Vitamin D deficiency impairs rituximab-mediated cellular cytotoxicity and outcome of patients with diffuse large B-cell lymphoma treated with but not without rituximab.
Bittenbring JT; Neumann F; Altmann B; Achenbach M; Reichrath J; Ziepert M; Geisel J; Regitz E; Held G; Pfreundschuh M
J Clin Oncol; 2014 Oct; 32(29):3242-8. PubMed ID: 25135997
[TBL] [Abstract][Full Text] [Related]
10. Serum albumin as a stable predictor of prognosis during initial treatment in patients with diffuse large B cell lymphoma.
Eatrides J; Thompson Z; Lee JH; Bello C; Dalia S
Ann Hematol; 2015 Feb; 94(2):357-8. PubMed ID: 25034876
[No Abstract] [Full Text] [Related]
11. Estimating the impact of rituximab on bcl-2-associated resistance to CHOP in elderly patients with diffuse large B-cell lymphoma.
Mounier N; Briere J; Gisselbrecht C; Reyes F; Gaulard P; Coiffier B;
Haematologica; 2006 May; 91(5):715-6. PubMed ID: 16670080
[TBL] [Abstract][Full Text] [Related]
12. Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma.
Collins-Burow B; Santos ES
Expert Rev Anticancer Ther; 2007 Mar; 7(3):257-73. PubMed ID: 17338647
[TBL] [Abstract][Full Text] [Related]
13. Addition of rituximab to reduced-dose CHOP chemotherapy is feasible for elderly patients with diffuse large B-cell lymphoma.
Shin HJ; Chung JS; Song MK; Kim SK; Choe S; Cho GJ
Cancer Chemother Pharmacol; 2012 May; 69(5):1165-72. PubMed ID: 22215473
[TBL] [Abstract][Full Text] [Related]
14. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial.
Delarue R; Tilly H; Mounier N; Petrella T; Salles G; Thieblemont C; Bologna S; Ghesquières H; Hacini M; Fruchart C; Ysebaert L; Fermé C; Casasnovas O; Van Hoof A; Thyss A; Delmer A; Fitoussi O; Molina TJ; Haioun C; Bosly A
Lancet Oncol; 2013 May; 14(6):525-33. PubMed ID: 23578722
[TBL] [Abstract][Full Text] [Related]
15. EBV-positive diffuse large B-cell lymphoma of the elderly: a case series from Peru.
Beltran BE; Castillo JJ; Morales D; de Mendoza FH; Quinones P; Miranda RN; Gallo A; Lopez-Ilasaca M; Butera JN; Sotomayor EM
Am J Hematol; 2011 Aug; 86(8):663-7. PubMed ID: 21761432
[TBL] [Abstract][Full Text] [Related]
16. Serum albumin retains independent prognostic significance in diffuse large B-cell lymphoma in the post-rituximab era.
Dalia S; Chavez J; Little B; Bello C; Fisher K; Lee JH; Chervenick P; Sokol L; Sotomayor E; Shah B
Ann Hematol; 2014 Aug; 93(8):1305-12. PubMed ID: 24590536
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors of primary gastric diffuse large B cell lymphoma: a retrospective study of 75 cases in China.
Wu YX; Liu B; Chen L; Li JH; Chen SQ
Ann Hematol; 2013 Jun; 92(6):861-2. PubMed ID: 23238898
[No Abstract] [Full Text] [Related]
18. Hope for very elderly patients with diffuse large B-cell lymphoma.
Ribera JM
Lancet Oncol; 2011 May; 12(5):412-3. PubMed ID: 21482185
[No Abstract] [Full Text] [Related]
19. High density of CD68+/CD163+ tumour-associated macrophages (M2-TAM) at diagnosis is significantly correlated to unfavorable prognostic factors and to poor clinical outcomes in patients with diffuse large B-cell lymphoma.
Marchesi F; Cirillo M; Bianchi A; Gately M; Olimpieri OM; Cerchiara E; Renzi D; Micera A; Balzamino BO; Bonini S; Onetti Muda A; Avvisati G
Hematol Oncol; 2015 Jun; 33(2):110-2. PubMed ID: 24711044
[No Abstract] [Full Text] [Related]
20. [Prognostic impact of bone marrow involvement (BMI) and therapies in diffuse large B cell lymphoma].
Yi SH; Xu Y; Zou DH; An G; Zhao YZ; Qi JY; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2009 May; 30(5):307-12. PubMed ID: 19799125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
